{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025458","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.280124+00:00","generated_at":"2026-06-22T13:54:07.281195+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024","bullets":["Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.","Cash and investments $69.8M at Sept 30, down from $117.8M at Dec 31, 2021; company expects funding into Q2 2024.","R&D expense $13.6M (down from $18.9M); G&A $3.9M (down from $4.1M).","Elarekibep Phase 2a asthma study enrollment continues; topline FEV1 results expected by Q3 2023.","PRS-220 Phase 1 first subject dosed; IND accepted for SGN-BB228; PRS-342 Phase 1 start within 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025458","json":"https://secwatch.observer/filing/0001437749-22-025458.json","markdown":"https://secwatch.observer/filing/0001437749-22-025458.md","text":"https://secwatch.observer/filing/0001437749-22-025458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/0001437749-22-025458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/pirs20220831_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:54:07.281195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c842c35d21f4607018cde89e37d975f410e5707","claim":"PALVELLA THERAPEUTICS, INC. reported financial results for the third quarter of 2022 ended September 30, 2022.","evidence_excerpt":"On November 2, 2022, Pieris Pharmaceuticals, Inc. (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/0001437749-22-025458-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022 ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}